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Background: The mechanism for inactivation of positive regulatory domain containing I (PRDM1), a newly
identified tumour suppressor gene in extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT) has not been well
defined. The aim of the present study was to investigate the expression of PRDM1 in EN-NK/T-NT and analyse its
downregulation by miRNAs.
Methods: PRDM1 and miRNA expression were evaluated in EN-NK/T-NT samples by immunohistochemical analysis,
qRT-PCR, and in situ hybridisation. Luciferase assays were performed to verify the direct binding of miR-223 to the
3′-untranslated region of PRDM1 mRNA. In addition, the effect of miR-223 on PRDM1 expression was assessed in
NK/T lymphoma cell lines by transfecting a miR-223 mimic or inhibitor to increase or decrease the effective
expression of miR-223. Overall survival and failure-free survival in EN-NK/T-NT patients were analysed using
Kaplan-Meier single-factor analysis and the log-rank test.
Results: Investigation of the downregulation of PRDM1 in EN-NK/T-NT cases revealed that PRDM1-positive staining
might be a favourable predictor of overall survival and failure-free survival in EN-NK/T-NT patients. However, the
negative staining of PRDM1 usually presented transcripts, suggesting a possible post-transcriptional regulation.
miR-223 and its putative target gene, PRDM1, exhibited opposite patterns of expression in EN-NK/T-NT tissues and
cell lines. Moreover, PRDM1 was identified as a direct target gene of miR-223 by luciferase assays. The ectopic
expression of miR-223 led to the downregulation of the PRDM1 protein in the NK/T-cell lymphoma cell line,
whereas a decrease in miR-223 restored the level of PRDM1 protein.
Conclusions: Our findings reveal that the downregulation of the tumour suppressor PRDM1 in EN-NK/T-NT samples
is mediated by miR-223 and that PRDM1-positive staining might have prognostic value for evaluating the clinical
outcome of EN-NK/T-NT patients.
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Extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT)
is a major type of natural killer (NK) cell neoplasm, and
its incidence is higher in Asia than it is in Western coun-
tries [1]. In our recent subtype distribution analysis of 142
Northern Chinese patients with peripheral NK/T cell
lymphomas, EN-NK/T-NT was the most prevalent subtype* Correspondence: zhangbo@bjmu.edu.cn; lixiaoting12@hotmail.com
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stated.(38.0%) [2]. This tumour usually presents with highly ag-
gressive clinical progression, but the prognosis is variable
and depends strongly on clinical factors. Our understand-
ing of the pathological prognostic factors of this disease
and the molecular characteristics of its pathogenesis re-
main limited.
In the last several decades, there has been extensive
research on the development and molecular basis of EN-
NK/T-NT implicating putative oncogenic mechanisms
in its marked aggressiveness and poor survival. Results
from gene expression profiling experiments suggest thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and the signal transducer and activator of transcription-3
signalling pathways may be involved in the angiogenesis,
immunosuppression, proliferation, and survival of EN-NK/
T-NT [3,4]. The overexpression of transcription factors
and aberrant microRNAs (miRNAs) has also been associ-
ated with tumour oncogenesis [5-7].
Previous genome-wide studies have identified a dele-
tion at 6q21 as the most frequent aberration in NK cell
neoplasms [8-10]. Further detailed analysis suggests that
positive regulatory domain containing I (PRDM1) is the
most likely target gene in del6q21 [11]. The inactiva-
tion of PRDM1 has been detected in neoplastic NK
cells, suggesting that it acts as a tumour suppressor
gene [12]. However, the loss of PRDM1 is also associ-
ated with promoter CpG island hypermethylation in
71% of NK cell lymphomas [12]. Moreover, PRDM1
expression can be detected independent of the 6q21 dele-
tion, and differences in the protein and mRNA levels of
PRDM1 have been observed [3,11,13]. These results sug-
gest a complex mechanism of PRDM1 inactivation in
NK/T lymphomas.
In the present study, we investigated the expression of
the PRDM1 protein in EN-NK/T-NT and the biological
role of PRDM1 in the evaluation of the clinical outcome
of EN-NK/T-NT patients. We also demonstrated a regu-
latory relationship between miR-223 and PRDM1, pro-




A total of 61 cases of EN-NK/T-NT of the upper aerodi-
gestive tract were retrieved from the Department of
Pathology, Peking University First Hospital. The histo-
logical specimens were fixed in 10% buffered formalin
and processed for routine paraffin-embedding. Histo-
logical sections with a thickness of 4 μm were stained
with haematoxylin and eosin and used for immunoper-
oxidase procedures. EN-NK/T-NT was diagnosed based
on combined morphological and immunophenotypical
findings (including positive CD56 and cytotoxic proteins),
as well as Epstein-Barr virus (EBV) positivity as deter-
mined by in situ hybridisation (ISH) with an EBV-encoded
small RNA (EBER-1) probe, according to the WHO classi-
fication [14].
The 61 patients included 34 males and 27 females with
ages ranging from 8 to 86 years (median 42 years). We
obtained clinical information on all cases, and follow-up
data for 35 patients. The follow-up period was defined
as starting from the date of initial diagnosis to the
patient’s death or last follow-up visit. Follow-up duration
ranged from 1 to 120 months (median 20 months) for
survivors.The study was approved by the ethics committee of
Peking University First Hospital (No. 2013[571]) and was
performed according to ethics committee regulations and
in compliance with the Declaration of Helsinki. The ethics
committee of Peking University First Hospital specifically
approved waiving the need for informed consent from
participants because this was a retrospective study using
archival surgical specimens with definitively established
diagnoses. Only a few specimens were obtained for study
to ensure the integrity of the remaining tissues. The pa-
tient data were obtained from the medical record library
through a double-blind process and were analysed an-
onymously. There was no risk of conflict of interest for
the patients.
Cell lines and cell culture
We utilised three NK/T-cell lymphoma cell lines: YT
[15], NKL [16], and NK92 [17]; the human chronic mye-
logenous leukaemia cell line K562; and the human embry-
onic kidney cell line 293 T. YT and NKL cells were obtained
from Beijing Hong Bokang Biological Technology (Beijing,
China). NK92, K562, and 293 T cells were purchased from
the Chinese Academy of Medical Sciences (Beijing,
China). YT, NKL, and K562 cells were cultured in RPMI
medium 1640 (Invitrogen, Carlsbad, CA, USA) with 10%
foetal bovine serum (Bio-Chrome, Germany). NK92 cells
were maintained in Alpha Minimum Essential medium
(Hyclone, UT, USA) with 12.5% horse serum and 12.5%
foetal bovine serum. For NKL and NK92 cells, which are
interleukin-2 (IL-2) dependent, the media were also sup-
plemented with 100 U/mL human recombinant IL-2
(PeproTech, London, UK). 293 T cells were cultured
in Dulbecco’s modified Eagle’s medium (Invitrogen,
Carlsbad, CA, USA) with 10% foetal bovine serum.
Immunohistochemistry
Immunohistochemistry (IHC) staining was performed
using the DAKO EnVision detection kit (Dako, Glostrup,
Denmark). The tissue sections were subjected to heat-
induced antigen retrieval in EDTA buffer (pH 9.0). A
primary antibody against PRDM1 (clone C14A4, Cell
Signaling Technology, Beverly, MA, USA) was used. A posi-
tive nuclear staining pattern was interpreted as representing
PRDM1 immunoreactivity. Based on Garcia and Nie’s inves-
tigations [18-20], positive expression of PRDM1 was defined
as nuclear staining in 10% or more of the tumour popula-
tion, and the stain grading was semi-quantitatively estimated
as follows: negative (0% to <10%), weak (10% to ≤50%
positive cells), or strong (>50% to 100% positive cells).
Samples from plasma cell myelomas, tonsils, and the
squamous epithelium of nasal mucosa were used as posi-
tive controls for PRDM1 staining. For the negative control
reactions, Phosphate buffer saline (PBS) was used instead
of the primary antibody.
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PRDM1α mRNA
We performed quantitative real-time polymerase chain
reaction (qRT-PCR) to detect PRDM1α mRNA level.
Total RNA was isolated from primary EN-NK/T-NT
formalin-fixed paraffin-embedded (FFPE) tissues and cell
lines (YT, NK92, NKL, and K562) using RNeasy FFPE
kit (Qiagen, Crawley, UK) and mirVana miRNA isolation
kit (Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s instructions. A pathologist esti-
mated the tumor region of the EN-NK/T-NT specimens
on hematoxylin and eosin–stained slides. The concen-
tration and quality of the total RNA was assessed with
a NanoDrop 2000 spectrophotometer (Thermo Fisher
Scientific, MA, USA). cDNA was synthesized from 1 μg
of total RNA using random primers and AMV Reverse
Transcriptase (Promega, Wisconsin, USA).
qRT-PCR assay for PRDM1α mRNA was performed
using the Applied Biosystems Power SYBR Green PCR
Master Mix and ABI-7300 real-time PCR system (Applied
Biosystems, Foster City, CA, USA). The PCR reaction was
conducted using 50 ng of cDNA template under the fol-
lowing conditions: 95°C for 10 min; 40 cycles at 95°C for
15 sec, 57°C for 30 sec, 72°C for 1 min. Primers for qRT-
PCR assay are as follows: PRDM1: forward (5′-TCCAG
CACTGTGAGGTTTCA-3′), reverse (5′-TCAAACTCA
GCCTCTGTCCA-3′); β-actin: forward (5′-ATCATGT
TTGAGACCTTCAACA-3′), reverse (5′-CATCTCTTGC
TCGAAGTCCA-3′). The quantitative level of PRDM1α
mRNA was normalized to β-actin using the cycle thresh-
old (Ct) method (2-△△Ct method). For each sample, 3 inde-
pendent experiments were made with triplicates for each
experiment. Samples from plasma cell myeloma and
tonsil were used as positive controls for PRDM1α mRNA
detection.
ISH detection
ISH for miR-223, miR-886-3p, and miR-34c-5p was per-
formed for 31 EN-NK/T-NTs, 10 peripheral T-cell lymph-
omas, and 13 inflammatory nasal mucosa specimens. The
presence of NK cells within the inflammatory nasal mu-
cosa specimens were identified by CD56 immunostaining.
Probes labelled with a locked nuclear acid (LNA)™ probe
for miR-223, miR-886-3p, and miR-34c-5p were designed
and generated by Bio Perfectus Technologies (Jiang-su,
China) according to sequences in the miRbase (Table 1).Table 1 Sequences of in situ hybridisation probes for miR-223
miRNA MiRbase no. Gen
hsa-miR-223 MIMAT0000280 Xq1
hsa-miR-886-3p MIMAT0004906 5q3
hsa-miR-34c-5p MIMAT0000686 11qThe ISH assays for miRNAs were performed as fol-
lows: FFPE tissues were routinely deparaffinised in xy-
lene and rehydrated with an ethanol gradient, treated
with 1 mg/ml Proteinase K for 10 min at 37°C, fixed
with 4% formaldehyde for 10 min, and then dehydrated
in ice-cold 90% ethanol. A 20-μL volume of hybridisa-
tion mixture consisting of 2 μL of the indicated LNA™
probe and 18 μL of a solution of 200 μg/mL salmon
sperm DNA, 1 mg/mL dithiothreitol (DTT), 50% form-
amide, 2× Denhardt’s, 1 mg/mL polyglucosan, and 2×
saline-sodium citrate (2× SSC) was applied to each slide.
The hybridisation reactions were performed overnight at
42°C in a humidified chamber. The sections were strin-
gently rinsed 3 times for 15 min each in 2× SSC at 37°C,
and endogenous peroxidases were blocked with 10%
H2O2 for 20 min. After 2 washes in 1× PBS for 10 min,
the slides were blocked with goat serum (1:100) for
30 min. The slides were then incubated with mouse
anti-digoxin antibody for 20 h at 4°C. The slides were
washed twice with 1× PBS, incubated with polymer aux-
iliary agent for 30 min, and washed with 1× PBS for
10 min. Goat anti-mouse secondary antibody was added
to the slides. After 2 washes with 1× PBS, DAB staining
was performed. miR-223-, miR-886-3p-, or miR-34c-5p-
positive EN-NK/T-NT tissue was used as a positive con-
trol for miR-223, miR-886-3p, or miR-34c-5p staining,
respectively. For negative control samples, the hybridisa-
tion reactions were performed with a sense probe. Cyto-
plasmic staining was interpreted as miRNA expression,
and positive expression was defined as staining of 10% or
more of the cells in each tumour. The grading was semi-
quantitatively estimated as follows: negative (0% to <10%),
weak (10% to ≤50% positive cells), or strong (>50% to
100% positive cells).
miRNA detection
To quantify miRNA levels in cell lines, qRT-PCR was
performed using the Taqman MicroRNA RT Kit, Taq-
man MicroRNA Assays, and TaqMan Universal Master
Mix II (Applied Biosystems, Foster City, CA, USA) in an
Applied Biosystems ABI-7300 real-time PCR system ac-
cording to the manufacturers’ recommendations. The
expression level of U6 RNA was used as an internal con-
trol for normalisation. The expression level of the indi-
cated miRNA relative to U6 was defined using the Ct
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free work environment during all protocols and utilised
diethylpyrocarbonate (DEPC)-treated water to prepare all
solutions.
Prediction of miRNA target genes
We predicted miRNA target genes using online prediction







The 3′-untranslated region (UTR) of human PRDM1
mRNA, which contains 3 putative miRNA target sites,
was PCR amplified from human genomic DNA using
the forward primer 5′-ATCGAGCTCAATCACGTCGG-
TATGATTGG-3′ and the reverse primer 5′-ACGCGT
CGACAGTTTGTTGTTCTAGCAAAGTA-3′ and sub-
sequently cloned into the pmirGLO Dual-Luciferase
miRNA Target Expression Vector (Promega, Wisconsin,
USA) using the SacI and SalI restriction sites to generate
the wild-type reporter vector PRDM1 3′-UTR.
Mutant reporter constructs were generated via the
QuikChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA) to generate 2 consecutive nucleotide
substitutions at the centre of each putative miR-223
binding site. The 3 putative binding sites in the PRDM1
3′-UTR were numbered 1 to 3 according to their posi-
tions from the distal to proximal end. The 3 putative
binding sites were mutated individually or in combin-
ation as follows: Mut1, Mut2, Mut3, Mut1 + 2, Mut1 + 3,
Mut2 + 3, and Mut1 + 2 + 3. The following primers were
used (mutant nucleotides indicated in bold): Mut1: 5′-
CACAGAAATAAAAAAGAGACTTTACCGCTGC-3′;
Mut2: 5′-CTGTAACTTCCAAGACACACAGCTTTTT
ATGTATC-3′; and Mut3: 5′-CTACTCAAAGTTAAAA
GAGACCAAAGTTACTGGC-3′. All constructs were
verified by sequencing.
Luciferase assays
For luciferase assays, 293 T cells were transiently co-
transfected with 150 ng of each of the reporter con-
structs (wild-type and mutant pmirGLO Dual-Luciferase
miRNA Target Expression Vector expressing both firefly
and renilla luciferase) and 8 pmol of mirVana miRNA
Mimic-223 or mirVana miRNA Mimic Negative Control
(Ambion, Austin, TX) in 24-well plates using Lipofecta-
mine™ 2000 (Invitrogen, Carlsbad, CA, USA).
We analysed luciferase activity in the cells at 24 h after
co-transfection using the Dual-Glo® Reporter Assay
System (Cat. # E1910, Promega, Wisconsin, USA) and aWallac Microbeta Trilux detector (Perkin Elmer, MA,
USA). The normalised firefly luciferase activity (firefly lu-
ciferase activity/renilla luciferase activity) of each con-
struct was compared to that of the pmirGLO Vector
control. For each transfection, the average luciferase activ-
ity from 4 independent experiments is reported.
Transfection assays and western blot
For electroporation, 2 × 106 YT cells were resuspended
in 300 μL RPMI 1640 medium without serum or antibiotics
and mixed with 150 pmol mirVana miRNA Mimic-223 or
mirVana miRNA Mimic Negative Control. Electroporation
was performed with a BTX ECM 830 electroporator (BTX,
San Diego, CA, USA) with a single pulse of 120 V and
20 ms. After transfection, the cells were immediately trans-
ferred to an incubator at 37°C and incubated for 5 min.
The transiently transfected cells were then cultured in pre-
warmed complete RPMI 1640 medium. The cell viability
was monitored by microscopic observation. The cells were
collected at 24 h and 48 h after electroporation and sub-
jected to total RNA isolation and western blot detection,
respectively. The transfection efficiency was evaluated by
detecting the fold increase of miR-223 using qRT-PCR.
In addition, we transiently transfected 2.5 × 105 NK92,
NKL, or K562 cells with 150 pmol of mirVana miR-223
inhibitor (Ambion, Austin, TX) using HiPerFect Trans-
fection Reagent (Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions. Transfection with the
mirVana miRNA Mimic Negative Control (Ambion,
Austin, TX) was used as a negative control. We collected
NK92, NKL, or K562 cells at 24 h and 48 h after trans-
fection for total RNA isolation and western blot detec-
tion, respectively. The detection of the fold decrease of
miR-223 in cells was performed to estimate the transfec-
tion efficiency by qRT-PCR.
Whole-cell lysates of transfected YT, NK92, NKL, or
K562 cells were separated by electrophoresis in 10% so-
dium dodecyl sulphate polyacrylamide gels. The gels were
electroblotted to polyvinylidene difluoride membranes
(Millipore), and the membranes were then blocked with
5% skim milk for 1 h at room temperature, followed by in-
cubation with a rabbit or mouse monoclonal antibody
against PRDM1 (PRDI-BF1) (1:1,000; Cell Signaling Tech-
nology, Beverly, MA, USA) or β-actin (1:5,000; Roche
Applied Science, Indianapolis, USA) overnight at 4°C.
Horseradish peroxidase-conjugated secondary antibodies
included anti-rabbit (1:5,000, Zhongshan, China) and anti-
mouse (1:5,000, Zhongshan, China). PRDM1 expression
was quantified by densitometry and normalised to β-actin.
Semi-quantitative RT-PCR
A total of 1 μg of total RNA from electroporated YT
cells was used to synthesise cDNA using AMV Reverse
Transcriptase (Promega, Wisconsin, USA). We assessed
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as an internal control. The primers of PRDM1α and
β-actin for RT-PCR were described as above. The
PCR conditions were as follows: 94°C for 3 min; 35
cycles at 94°C for 30 sec, 57°C for 30 sec, 72°C for
30 sec; and a final extension at 72°C for 5 min. The
expected fragment sizes were 104 bp for PRDM1 and
318 bp for β-actin. We analysed the reactions using
agarose gel electrophoresis.
Statistical analysis
We used the Mann–Whitney U-test or Student’s t-test
to analyse differential miRNA expression as determined
by qRT-PCR miRNA assays and western blot result, and
we estimated the statistical significance of the level of
miRNA expression as determined by ISH using a χ2 test
or Fisher’s exact test. The Spearman rank correlation co-
efficient test was utilised to correlate the expression of
PRDM1 and miR-223. Treatment outcomes were mea-
sured by failure-free survival (FFS) and overall survival
(OS). FFS was defined as the time from initial diagnosis
to progression, relapse, or death from any cause. OS was
calculated as the time from initial diagnosis to death from
any cause or to last follow-up. The estimates of FFS and
OS were calculated using the Kaplan-Meier method and
compared to log-rank tests and multivariate analysis (Cox
model). Differences were considered statistically signifi-
cant when the 2-sided P value was less than 0.05. All ana-
lyses were performed using SPSS (Statistical Package for
the Social Sciences) 13.0 software (Chicago, IL).
Results
Evaluation of PRDM1 expression in EN-NK/T-NT samples
by IHC
The expression of PRDM1 protein in 61 primary EN-
NK/T-NT tumour specimens was assessed by IHC. As
shown in Figure 1A and B, PRDM1 positive staining was
observed in the nuclei of tumour cells. The expression
of PRDM1 was negative in the majority of EN-NK/T-NT
samples (46/61, 75.41%) (Figure 1C), and the remain-
ing EN-NK/T-NT cases (15/61, 24.59%) showed only
weak staining (10%-50% positive cells) for PRDM1
(Figure 1A, B); no EN-NK/T-NT samples were strongly
positive for PRDM1. By contrast, strong positive staining
was observed in all the positive control cases, including
samples from plasma cell myeloma (Figure 1D), tonsil
(Figure 1E), and the squamous epithelium of nasal
mucosa (Figure 1F); more than 50% of the tumour
cells in these samples showed nuclear staining, and
the staining intensity of the positive cells was dis-
tinctly stronger than that of the EN-NK/T-NT cases.
Thus, these results demonstrate that PRDM1 protein
expression is downregulated in EN-NK/T-NT cases,
similar to results from a previous article [18].Correlation between PRDM1 expression and the clinical
factors of EN-NK/T-NT patients
To identify the possible biological role of PRDM1 ex-
pression in EN-NK/T-NT, we analysed the correlation
between the expression of PRDM1 and clinical findings
in EN-NK/T-NT patients. Follow-up study of 35 cases
showed mean and median survival periods of 32 months
and 20 months, respectively. The 5-year OS rate was
37.14%. The clinical characteristics of the patients in-
cluding sex, age, Ann Arbor Stage and patient outcome,
and the results of the statistical analysis are summarised
in Table 2.
A univariate analysis of advanced stage (III/IV) disease
showed significantly downregulated expression levels of
PRDM1 (P = 0.009, Table 2). As expectedly, the frequency
of PRDM1 expression distribution was significantly differ-
ent among living and deceased patients (P = 0.038) and
had a significant effect on the 5-year OS (P = 0.045). Not-
ably, Kaplan-Meier single-factor analysis and the log-rank
test revealed that PRDM1-positive staining predicted a
favourable effect on OS and FFS (Table 2, Figure 1G
and H), suggesting that the expression of PRDM1 may be
an important predictive factor in EN-NK/T-NT patients.
In addition, multivariate analysis and Cox regression com-
bining Ann Arbor Stage revealed that PRDM1 expression
status did not reach statistical significance as an independ-
ent predictor of 5-year OS (P = 0.556) and FFS (P = 0.727),
but Ann Arbor Stage was an independent predictor of 5-
year OS (P = 0.002) and FFS (P = 0.003).
Detection of PRDM1 transcripts in EN-NK/T-NT
As mentioned earlier in the Background, the inactivation
of PRDM1 cannot be attributed only to 6q21 deletion.
Epigenetic regulation such as translational suppression
or DNA methylation may also be involved [12]. To fur-
ther clarify the molecular mechanism of PRDM1 inacti-
vation, we compared the PRDM1 protein expression
with the PRDM1 transcript level in EN-NK/T-NT speci-
mens and NK/T-cell lymphoma cell lines. As shown in
Figure 2A, we set plasma cell myeloma (case #1) as having
strong expression of PRDM1 protein as 100%. Case #2 in-
dicates tonsil, as a control with relative high percentage of
PRDM1 protein positive cells. Case #3 to #18 indicates 16
EN-NK/T-NT cases. We observed the discordance be-
tween PRDM1 transcript and protein expression in most
EN-NK/T-NT cases (9/16, 56.25%) (Figure 2A). High level
of PRDM1α mRNA relative to plasma cell myeloma and
tonsil was detected in 9 EN-NK/T-NT cases (#3, 6, 7, 8,
10, 11, 14, 15, and 16) by qRT-PCR, but the percentage of
PRDM1 positive tumor cells was low or absent in IHC, in-
dicating that the degree of PRDM1 transcript did not
translate to the same extent as PRDM1 protein. These
findings suggest that the decreased PRDM1 protein may
be associated with post-transcriptional regulation.
Figure 1 (See legend on next page.)
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Figure 1 Immunohistochemistry (IHC) and prognostic analysis of PRDM1 in extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT)
cases. Examples of IHC analysis of PRDM1 in EN-NK/T-NT specimens and control samples. (A) PRDM1 staining in the nuclei of tumour cells was
observed in approximately 50% of tumour cells in 1 case of EN-NK/T-NT; most cells had moderate to weak nuclear staining. (B) PRDM1 was
expressed in approximately 10% of tumour cells in 1 case of EN-NK/T-NT. (C) No PRDM1 staining was detected in 1 case of EN-NK/T-NT. In the
control cases, strong nuclear PRDM1 immunostaining was observed in plasma cell myeloma (D), the epithelium and germinal centre of the tonsil
(E), and the squamous epithelium of the nasal mucosa (F) (all by IHC; A, B, C, and F are shown at 400× magnification; D and E are shown at
200× magnification). (G) and (H) Kaplan-Meier survival analysis demonstrated that PRDM1 expression predicted a favourable effect on overall
survival (OS) and failure-free survival (FFS) of EN-NK/T-NT patients (P = 0.084 and P = 0.042, respectively).
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vealed the discrepancy between PRDM1 transcript and
its protein in some NK/T-cell lymphoma cell lines. As
shown in Figure 2B and Figure 2C, in contrast to YT or
NK92 cells, which presented consistent levels in both
transcription and protein of PRDM1, PRDM1 transcripts
in NKL cells are estimated at about 73.0% of those in
YT cells (Figure 2B), whereas PRDM1α protein is just
6.0% (Figure 2C). Similarly, PRDM1α transcript and pro-
tein levels in K562 cells, the human chronic myeloge-
nous leukaemia cell line, are 40.1% and 9.3% of YT cells,
respectively (Figure 2B, C). Therefore, what we have ob-
served in EN-NK/T-NT tissues and cell lines strongly
imply the possibility that post-transcriptional regulation
may abrogate the PRDM1 protein expression.Table 2 Correlation of PRDM1 and miR-223 expression with c
PRDM1 expression
n Percent Negative Positive P
Patients 61
male 34 55.74 26 8 0
female 27 44.26 20 7
Age (year) 61
<40 29 47.54 21 8 0
40-60 20 32.79 17 3
>60 12 19.67 8 4
StageΔ 46
І/ІІ 18 39.13 9 9 0
III/IV 28 60.87 24 4
Outcome 35
alive 12 34.29 6 6 0
dead 23 65.71 20 3
5-year OS 35
Mean ± SD 39.49 ± 9.62 64.02 ± 11.48 0
OS 35
Mean ± SD 44.72 ± 10.41 64.02 ± 11.48 0
FFS 35
Mean ± SD 26.50 ± 5.60 57.41 ± 11.60 0
※NA, not analyzed, because of limited sample size.
△Ann Arbor Stage.Altered miRNA expression in EN-NK/T-NT lymphoma
miRNAs are a novel class of non-coding small RNAs
that negatively regulate protein expression via specific
binding to their target sites in the 3′-UTR of their target
mRNAs, initiating a translational blockade or the degrad-
ation of target mRNAs. We have previously confirmed the
upregulation of miR-223 and miR-886-3p and the down-
regulation of miR-34c-5p in EN-NK/T-NT cases; these
changes are significantly different from those occurring in
inflammatory nasal mucosa based on global miRNA ex-
pression profiling and qRT-PCR miRNA assays [21]. We
hypothesised that in addition to the frequent deletions and
DNA methylation reported previously, aberrant miRNAs
may be responsible for the downregulation of the PRDM1
protein in EN-NK/T-NT.linical factors and prognostic value
miR-223 expression
n Percent Negative Positive P
31
.829 19 61.29 5 14 0.704
12 38.71 4 8
31
.463 13 41.94 4 9 NA※
11 35.48 2 9
7 22.58 2 5
26
.009 9 34.62 3 6 0.661
17 65.38 4 13
21
.038 8 38.10 3 5 0.325
13 61.90 2 11
21
.045 53.40 ± 18.41 45.70 ± 10.05 0.504
21
.084 53.40 ± 18.41 52.84 ± 10.70 0.784
21
.042 43.20 ± 16.89 38.99 ± 7.84 0.691
Figure 2 Discrepancy between PRDM1α mRNA and protein expression in extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT).
(A) The relative levels of PRDM1α mRNA by qRT-PCR and the corresponding PRDM1 protein by immunohistochemistry (IHC) were analysed in
16 EN-NK/T-NT cases, one plasma cell myeloma, and one tonsil case. Case #1 is plasma cell myeloma. Case #2 is tonsil, and cases #3 to #18 are
16 EN-NK/T-NT cases. Levels of PRDM1α mRNA in the tonsil and EN-NK/T-NT cases were estimated relative to that in plasma cell myeloma
(arbitrarily set as 100%), which showed strong expression of PRDM1 protein. The data of PRDM1α mRNA by qRT-PCR are presented as mean ± SE
of 3 independent experiments. Expression of PRDM1 protein in formalin-fixed paraffin-embedded sections of EN-NK/T-NT specimens, plasma cell
myeloma, and one tonsil case was determined by immunostaining and assessed by the percentage of PRDM1 positive cells. Of 16 EN-NK/T-NT
cases, 9 cases (#3, 6, 7, 8, 10, 11, 14, 15, and 16) showed high level of PRDM1α mRNA relative to plasma cell myeloma by qRT-PCR but low or
absent percentage of PRDM1 protein positive tumor cells by IHC. (B) PRDM1α mRNA was determined by qRT-PCR in NK/T-cell lymphoma cell
lines YT, NK92, and NKL, and the human chronic myelogenous leukaemia cell line K562 (mean ± SE of 3 independent experiments). The level of
PRDM1α transcript was assessed relative to that in YT cells (arbitrarily considered as 100%). PRDM1α mRNA levels in NK92, NKL, and K562 cells
were 15.0%, 73.0%, and 40.1% of those in YT cells, respectively. (C) The expression of PRDM1α protein was detected in cell lines by western blot.
The density of PRDM1α in YT cells was set as 100%, and the levels in NK92, NKL, and K562 cells were calculated as 5.0%, 6.0%, and 9.3% of YT
cells, respectively.
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EN-NK/T-NT, we used ISH to determine the expression
status of miR-223, miR-886-3p, and miR-34c-5p in tumour
cells. ISH analysis of FFPE tissues from EN-NK/T-NT
demonstrated strong expression of miR-223 and miR-
886-3p in the cytoplasm of EN-NK/T-NT tumour cells
and weak to no staining in peripheral T-cell lymphoma or
inflammatory nasal mucosa; miR-34c-5p staining was
weak in most samples from these 3 groups. Representative
ISH results for miR-223, miR-886-3p, and miR-34c-5p are
shown in Figure 3. As shown in Figure 4A, the expression
of miR-223 was statistically greater in EN-NK/T-NT can-
cer cells than in peripheral T-cell lymphoma (P = 0.013)
and inflammatory nasal mucosa samples (P = 0.043). Inaddition, miR-886-3p also upregulated in EN-NK/T-NT
samples, which was significantly different from peripheral
T-cell lymphoma (P = 0.028) and inflammatory nasal
mucosa samples (P = 0.022) (Figure 4B). Nevertheless,
miR-34c-5p expression showed no significant differ-
ence between primary EN-NK/T-NT, peripheral T-cell
lymphoma, and inflammatory nasal mucosa tissues (P =
1.000 and P = 0.254, respectively) (Figure 4C). In addition,
the ISH results of miR-223, miR-886-3p, and miR-34c-5p
were cross-validated with qRT-PCR results in 15 EN-NK/
T-NT FFPE cases. Both the ISH results and the previous
qRT-PCR microRNA assays were highly consistent in the
EN-NK/T-NT cases (91.67% consistency for miR-223,
75.00% for miR-886-3p, and 58.33% for miR-34c-5p),
Figure 3 Representative cases of miRNA expression identified by in situ hybridisation (ISH). ISH analysis revealed characteristic
upregulation of miR-223 in the cytoplasm of extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT) tumour cells (A1), whereas no signal was
detected in peripheral T-cell lymphoma (A2) and inflammatory nasal mucosa (A3). In addition, miR-886-3p was also overexpressed in the
cytoplasm of EN-NK/T-NT tumour cells (B1) but was negative in peripheral T-cell lymphoma (B2) and inflammatory nasal mucosa (B3). There
were no miR-34c-5p signals in EN-NK/T-NT samples (C1), peripheral T-cell lymphoma samples (C2), or inflammatory nasal mucosa samples (C3).
All images show ISH at 400x magnification.
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of miR-223 and miR-886-3p. Thus, the upregulation of
miR-223 and miR-886-3p might be involved in the onco-
genesis of EN-NK/T-NT and associated with PRDM1
inactivation.
Bioinformatic prediction of potential miRNA target genes
To identify potential miRNA:mRNA target interactions,
we utilised bioinformatics prediction algorithms including
Target Scan Human 6.0, PICTAR-VERT, MICRORNA.
ORG, and DIANA-MICROT. Bioinformatics prediction al-
gorithms did not predict a target interaction between miR-
886-3p and PRDM1 mRNA. Notably, 3 putative miR-223
binding sites were predicted in the 3'-UTR of the PRDM1
mRNA (Figure 5A). Moreover, the bases required for effi-
cient pairing between the 5'-end sequence, also known asthe “seed sequence”, of miR-223 and the complementary
sequences of PRDM1 3′-UTR are evolutionarily conserved
(Figure 5A), suggesting a potential regulatory role of miR-
223 for PRDM1 expression.
The expression of PRDM1 in EN-NK/T-NT correlates with
miR-223
To investigate the association between PRDM1 and
miR-223 in EN-NK/T-NT cases, we performed a correla-
tive analysis between PRDM1 immunostaining and miR-
223 ISH. As shown in the scatter diagram (Figure 6A),
there is a significant inverse correlation between the levels
of PRDM1 expression and miR-223 expression in EN-NK/
T-NT cases (P < 0.001). Only 2 cases exhibited similar ex-
pression levels of miR-223 and PRDM1. Figure 6B shows
one representative case of this inverse correlation in which
Figure 4 Statistical analysis of miR-223, miR-886-3p, and miR-34c-5p expression by in situ hybridisation (ISH). The expression percentage
of miR-223, miR-886-3p, and miR-34c-5p was statistically analysed in extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT), peripheral T-cell
lymphoma and inflammatory nasal mucosa cases by ISH. Statistically, ISH results revealed that the expression level of miR-223 was significantly
higher in EN-NK/T-NT cases than in peripheral T-cell lymphoma (A, ※P = 0.013) and in inflammatory nasal mucosa (A, ※※P = 0.043). Similarly,
miR-886-3p expression upregulated in EN-NK/T-NT cases compared to peripheral T-cell lymphoma (B, #P = 0.028) and inflammatory nasal mucosa
(B, ##P = 0.022). However, the expression level of miR-34c-5p (C, ΔP = 1.000 and ΔΔP = 0.254) did not differ significantly between these 3 groups.
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IHC indicated no PRDM1 expression in EN-NK/T-NT.
In addition, we assessed the correlation between
PRDM1 and miR-223 using qRT-PCR and western blot
analysis of 3 NK/T lymphoma cell lines: YT, NK92, and
NKL. Since K562 cells have a high level of miR-223 but
lack PRDM1 expression, we used this as a control cell
line. The level of miR-223 was much lower in YT cells
than in NK92 and NKL cells (Figure 6C), and conversely,
PRDM1α protein was markedly higher in YT cells than
in NK92 and NKL cells (Figure 6D).
Taken together, these results demonstrate an opposing
expression pattern of PRDM1 protein and miR-223 in
primary EN-NK/T-NT tissues or in cultured NK/T
lymphoma cells, suggesting that miR-223 might regulate
the expression of PRDM1.
Identification of PRDM1 as a direct target gene of miR-223
To identify PRDM1 3′-UTR as a direct target gene of
miR-223, we constructed a luciferase reporter plasmidcontaining the PRDM1 3′-UTR by inserting the 3
predicted target sequences into the pmirGLO expres-
sion vector. qRT-PCR analysis revealed that miR-223
is not endogenously expressed in 293 T cells. Thus, lucif-
erase reporter assays were performed with 293 T cells
by co-transfecting pmirGLO Expression-PRDM1-3′
UTR with mirVana miRNA Mimic-223 (WT group) or
Mimic Negative Control (NC group). The luciferase activ-
ity of the WT group decreased to 48.08% upon the
ectopic expression of miR-223 compared to the NC group
(Figure 5B), demonstrating the direct effect of miR-223 on
the PRDM1 3′-UTR.
To clarify the interaction between miR-223 and its pre-
dicted target sequences, a panel of reporter constructs con-
taining individual or combined mutations in the predicted
target sequences was generated as shown in Figure 5C.
Each of these reporters was individually transfected into
293 T cells with the miR-223 mimic. Mutagenesis effect-
ively restored luciferase activity to varying degrees (74.87%
for Mut1, 85.21% for Mut2, and 74.84% for Mut3,
Figure 5 Verification of PRDM1 as a direct target gene of miR-223. (A) The complementarity between miR-223 and its 3 conserved putative
binding sites in the PRDM1 3′-untranslated region (UTR) is highlighted in bold between different species. (B) Luciferase reporter assays were
performed in 293 T cells that were co-transfected with miR-223 mimic and wild type pmirGLO expression-PRDM1-3′UTR (WT) reporter plasmid or
mutant pmirGLO expression-PRDM1-3′UTR reporter plasmids harbouring point mutations in the target sites for miR-223 (Mut1, Mut2, Mut3,
Mut1 + 2, Mut1 + 3, Mut2 + 3, and Mut1 + 2 + 3). Mimic Negative Control was used as a negative control (NC). Firefly luciferase activity was
normalised relative to Renilla luciferase activity. Transfection of the miR-223 mimic resulted in a marked decrease in luciferase activity in the WT
group compared to the NC group (48.08%). Mutations in each of the putative target sites or combined mutations restored luciferase activity to
varying degrees: 74.87% for Mut1, 85.21% for Mut2, 74.84% for Mut3, 90.76% for Mut1 + 2, 87.55% for Mut1 + 3, 81.15% for Mut2 + 3, and 94.51%
for Mut1 + 2 + 3. Data are presented as mean ± SE of 4 independent experiments. (C) Two nucleotides in the middle of each target site were
mutated to generate different mutant luciferase reporters.
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target sites induced an increased restoration of luciferase
activity (90.76% for Mut1 + 2, 87.55% for Mut1 + 3, and
81.15% for Mut2 + 3, Figure 5B). Notably, the repression
of luciferase activity by miR-223 was nearly eliminated
(94.51%) when all 3 predicted target sites were mutated
(Figure 5B). In addition, luciferase activity recovered more
strongly with the mutation of target site 2 compared to
mutations of the other 2 target sites, implying that target
site 2 may play a more important role in the direct binding
between miR-223 and the PRDM1 3′ -UTR.
Taken together, this experimental evidence demon-
strates that the 3 predicted target sites in the PRDM1
3′-UTR all contribute to the direct post-transcriptional
regulation of PRDM1 expression by miR-223, and that a
differential and cooperative effect exists between these 3
putative binding sites.Ectopic expression of miR-223 leads to the downregulation
of the PRDM1 protein
We examined the effect of miR-223 on the PRDM1 pro-
tein by transfecting a miR-223 mimic or negative control
into YT cells. We used YT cells because they expressed
the lowest endogenous level of miR-223 relative to
NK92, NKL, and K562 cells. qRT-PCR analysis identified
significantly increased level of miR-223 in YT cells trans-
fected with the miR-223 mimic compared to the nega-
tive control (Figure 7A, P < 0.001). The expression level
of the PRDM1α protein decreased to 54.44% in YT cells
treated with ectopic miR-223 relative to YT cells treated
with the negative control (Figures 7B and C, P = 0.008);
however, there was no significant difference in the mRNA
level of PRDM1α between these 2 groups (Figure 7D),
demonstrating that PRDM1α protein expression may be
directly downregulated by miR-223 via the inhibition
Figure 6 Correlation of the expression of PRDM1 and miR-223 in extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT). (A) The
expression of PRDM1 and miR-223 in EN-NK/T-NT cases were analysed by immunohistochemistry (IHC) and in situ hybridisation (ISH), respectively,
and the result is shown as a scatter diagram. As described in the Materials and Methods section, these results were semi-quantitatively scored into
3 grades according to the number of positive tumour cells. In this figure, the numbers of ordinate are as follows: “1” indicates negative (0% to <10%
positive cells), “2” indicates weak (10% to ≤50% positive cells), and “3” indicates strong (>50% to 100% positive cells). Statistically, a significantly
opposing correlation was observed between the levels of PRDM1 protein and miR-223 expression in 31 EN-NK/T-NT cases (P < 0.001); only 2 cases
had the same relative expression levels of PRDM1 and miR-223. (B) One representative case of EN-NK/T-NT was negative for PRDM1 by IHC but
strongly positive for miR-223 by ISH (400×). (C) qRT-PCR analysis revealed much lower levels of miR-223 in YT cells than in NK92, NKL, and K562 cells
(mean ± SE of 3 independent experiments). (D) Western blotting revealed markedly higher levels of PRDM1α protein in YT cells than in NK92, NKL,
and K562 cells.
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mRNA.
Restoration of PRDM1 expression by reducing miR-223
To test the effect of miR-223 reduction on PRDM1 pro-
tein in NK92, NKL, and K562 cells, a miR-223 inhibitor
was transfected into cells to reduce the endogenous ex-
pression of miR-223. qRT-PCR revealed that the miR-
223 inhibitor reduced the levels of endogenous miR-223in NKL and K562 cells to 40.12% (P = 0.017) and 45.10%
(P = 0.044), respectively, of the negative control (Figure 7E),
whereas, the level of PRDM1α protein increased to 220%
(P = 0.040) and 234% (P = 0.022), respectively (Figure 7F).
This result provides further experimental evidence
that PRDM1α is directly silenced by miR-223. However,
we found no distinct changes in PRDM1α expression in
NK92 cells (Figure 7F, P = 1.000), even though the level
of endogenous miR-223 diminished to 55.90% (Figure 7E,
Figure 7 Endogenous PRDM1 protein expression is affected by increased miR-223 or decreased miR-223. A miR-223 mimic or mimic
negative control (NC) was transfected into YT cells by electroporation. (A) qRT-PCR analysis revealed a significantly increased level of miR-223 in
YT cells transfected with miR-223 mimic compared to NC. The results were confirmed in 3 independent experiments with data presented as
mean ± SE (※P < 0.001). (B) Western blot showed that PRDM1α protein level was markedly diminished (54.44% relative to YT-NC, normalised to
β-actin) in YT cells transfected with miR-223 mimic. YT-NC was adjusted to 100%. Results were quantified by densitometry in 3 independent
experiments (mean ± SD) (#P = 0.008). (C) A representative image of PRDM1α protein expression in YT cells as detected by western blot.
(D) RT-PCR and agarose gel electrophoresis showed ectopic expression of miR-223 with no effect on PRDM1α transcript. NK92, NKL, and K562 cells
were transfected with miR-223 inhibitor or NC with HiPerFect Transfection Reagent. (E) Compared to NC, the level of endogenous miR-223 was
significantly decreased in NK92, NKL, and K562 cells by qRT-PCR analysis. The data are presented as mean ± SE of 4 independent experiments
(ΔP = 0.026, ΔΔP = 0.017, and ΔΔΔP = 0.044). (F) Semi-quantitative analysis by densitometry demonstrated that the PRDM1α protein was restored to
220% and 234% by miR-223 inhibition in NKL and K562 cells, respectively, compared to NC, but the level of PRDM1α protein in NK92 cells was not
significantly affected. The data are presented as mean ± SD of 4 independent experiments (§P = 1.000, §§P = 0.040, and §§§P = 0.022). (G) Representative
western blot images of PRDM1α protein levels in NK92, NKL, and K562 cells are shown.
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regulate PRDM1 expression. Representative images of
PRDM1α protein expression in NK92, NKL, and K562
cells are shown in Figure 7G.
Association of miR-223 with clinical factors of EN-NK/T-NT
patients
We attempted to analyse the potential biological role of
miR-223 expression in 21 EN-NK/T-NT cases. miR-223
positive staining showed no significant correlation with
sex, age, tumour stage, or patient status and had no sig-
nificant effects on the 5-year OS rate, OS, or FFS (Table 2,
Figure 8A and B). The lack of a significant association be-
tween miR-223 expression and clinical factors in EN-NK/
T-NT patients may be due to the limited sample size; fu-
ture studies should include more patients.
Discussion
It is becoming clear that PRDM1 functions as a tumour
suppressor gene in lymphomas. The inactivation or
downregulation of PRDM1 appears to be a common
event in activated B cell-like diffuse large B cell lymph-
oma and is associated with various events including mis-
sense mutations, biallelic gene deletions, or the post-
transcriptional inhibition of let-7 [19,22,23]. Although
research on PRDM1 in NK/T-cell lymphoma is rapidly
increasing [18], few studies have examined PRDM1 in
Asian EN-NK/T-NT patients, which constitute a large
portion of the incidence of this disease in the world.
The present investigation demonstrated that immuno-
staining of PRDM1 might be prognostic in EN-NK/T-NT.
We observed only weak PRDM1 positivity in about one
quarter of the EN-NK/T-NT cases (24.59%), consistent
with the findings of Iqbal and Karube et al., who reported
low levels of PRDM1 expression in NK-cell neoplasms
and cell lines compared to normal NK cells [11,13].Figure 8 Kaplan-Meier survival analysis of miR-223 in extranodal NK/
Kaplan-Meier survival analysis, no correlation was investigated between the
and failure-free survival (FFS) (B, P = 0.691) of EN-NK/T-NT patients.However, Ng et al. reported PRDM1 overexpression in
50% (17/34) of NK/T-cell lymphomas [7]. Therefore, stud-
ies describing the detection of PRDM1 by IHC are still
limited and inconsistent. Because PRDM1 expression
could be an important predictor of EN-NK/T-NT, stand-
ardisation of immunohistochemical procedures (such as
antibodies and the conditions for antigen retrieval and
staining evaluation) is necessary to reduce the inconsist-
ency of PRDM1 protein measurements.
In our study, univariate analysis revealed that the fre-
quency of PRDM1-positive expression was significantly
higher in early-stage (I/II) than in advanced-stage (III/IV)
tumours. We found the advanced stage to be a poor pre-
dictor in EN-NK/T-NT cases [2]. Indeed, the important
role of PRDM1 in predicting a good outcome is supported
by our investigation of its positive effect on patient status,
5-year OS, OS, and FFS in EN-NK/T-NT. The ectopic
introduction of PRDM1 in the NK/T lymphoma cell
line NKL can induce cell cycle arrest and apoptosis, and
the knockdown of PRDM1 in NK cells promotes growth
[12,13]. PRDM1 can also promote the apoptosis of tumour
cells by specifically suppressing MKI67 and proliferating
cell nuclear antigen [24]. In conjunction with previous in-
vestigations, our results imply that PRDM1 staining may
be used as a positive marker for evaluating the clinical out-
come of EN-NK/T-NT patients. However, multivariate
analysis demonstrated that PRDM1 expression was not an
independent predictor of clinical outcome in our study.
This finding may be due to our limited cohort, and we will
attempt to enlarge the cohort and perform further analysis
of the significance of PRDM1 expression in future studies.
Previous studies primarily attribute the inactivation of
PRDM1 to the 6q21 deletion, which occurs in 20 to 43%
of EN-NK/T-NT samples and cell lines [3,8,11,12]. Con-
tradicting this view, PRDM1 has been shown to be
expressed independent of the presence or absence of theT-cell lymphoma, nasal type (EN-NK/T-NT) patients. According to
expression status of miR-223 and on overall survival (OS) (A, P = 0.784)
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can be induced by promoter methylation [13]. Ng et al.
reported that the expression of PRDM1 can be directly
downregulated by miR-30b in NK/T-cell lymphoma [7].
The downregulation of PRDM1 protein in B and T cell
lymphomas may be ascribed to different mechanisms.
miR-9, let-7a, and miR-30b directly downregulate
PRDM1 protein [7,20], and BCL6 and LMP1 repress
PRDM1 transcription [25,26]. T-bet and Ets-1 also regu-
late the expression and function of PRDM1 protein
[27,28]. Therefore, based on current knowledge, the inacti-
vation of PRDM1 may be resulted from the 6q21 deletion,
DNA methylation, miRNA inhibition, and other distinct
signalling pathways. In particular, it has been noted that
some cases or cell lines of lymphoma with high levels of
PRDM1 mRNA fail to express PRDM1 protein, which im-
plies that post-transcriptional regulation may account for
the loss of the PRDM1 protein [3,11,13,19,29]. More
importantly, our observations demonstrated the discord-
ance of high PRDM1 mRNA levels and downregulated
protein expression in large parts of EN-NK/T-NT cases
and some cell lines, increasing the possibility that the
steady state of PRDM1 protein may be associated with
post-transcriptional regulation.
Our data provide evidence for the downregulation of
PRDM1 by miR-223 at the post-transcriptional level as
part of the pathogenesis of EN-NK/T-NT. First, the level
of the PRDM1 expression was reciprocal to miR-223
expression in EN-NK/T-NT cases or cultured NK/T
lymphoma cell lines. Second, miR-223 directly targeted
the PRDM1 3′-UTR, as evidenced by luciferase reporter
assays. Third, the PRDM1α protein was markedly dimin-
ished by the exogenous overexpression of miR-223 in YT
cells and restored by miR-223 reduction in NKL and K562
cells, while PRDM1α mRNA was not affected. Thus, the
post-transcriptional silencing of PRDM1 by miR-223
might well explain the discrepancy between high PRDM1
mRNA and low protein levels in EN-NK/T-NT found in
both our study and in previous reports [3,11,13]; and the
targeting of PRDM1 by miR-223 might be an important
mechanism of PRDM1 gene inactivation. However, we
also noted that the restoration of PRDM1α protein did
not occur in NK92 cells; low levels of both PRDM1 tran-
script and protein were detected in 6 EN-NK/T-NT tis-
sues and NK92 cells, and the methylation in the CpG
island of PRDM1 gene reportedly occurs in NK92 cells
[11]. Thus, it seems that PRDM1 may be regulated by
other parallel regulatory pathways in addition to miR-223.
The identification of miRNAs is a rapidly evolving
field, and miRNAs are emerging as central players in the
regulation of epigenetic expression [30-32]. The dysregu-
lation of miRNAs has been linked to various types of
cancer including lymphocytic malignancy [30,32,33].
miR-223 is located on chromosome Xq12 and plays anessential role in promoting granulocytic differentiation.
It is associated with the suppression of erythrocytic dif-
ferentiation [34-36]. A recent study demonstrated that
the overexpression of miR-223 significantly downregulates
the mRNA levels of the tumour suppressor gene FBXW7,
resulting in an increase in the levels and activity of en-
dogenous cycling E protein and genomic instability [37].
Moreover, higher expression levels of miR-223 correlate
with extranodal marginal-zone lymphoma of mucosa-
associated lymphoid tissue of the stomach [38]. Markedly
increased expression of miR-223 has also been observed
in some T-cell acute lymphoblastic leukaemia cases with
poor clinical outcomes [39]. Therefore, the function of
miR-223 appears to differ in distinct tissues, and these
functions may be ascribed to the complexity of the inter-
action between a miRNA and its target genes and cell
type-specific biological effects. Through ISH, we observed
specific overexpression of miR-223 in EN-NK/T-NT FFPE
samples compared with peripheral T-cell lymphoma
and inflammatory nasal mucosa samples. Furthermore,
miR-223 directly downregulated expression of the tumour
suppressor gene PRDM1, indicating its potential import-
ance in an epigenetic or post-transcriptional role in EN-
NK/T-NT.
The mechanism responsible for aberrant overexpres-
sion of miR-223 in EN-NK/T-NT is unclear. Although
the overexpression of miRNAs in B-cell lymphoma is
due to genomic amplification [40], no genomic amplifi-
cations or translocations of the Xq12 locus have been re-
ported in several genome-wide analyses of NK/T-cell
lymphomas [3,8,11]. The infection of NK cells by EBV
is a potential alternative mechanism because nearly all
NK/T-cell lymphomas are associated with EBV infection.
In our study, all miR-223-positive cases of EN-NK/T-NT
showed EBV infection, implying that EBV infection may
be responsible for miR-223 overexpression. Indeed, the
upregulation of miR-223 has been observed after EBV
transformation of lymphoblastoid cells [41]. Motsch et al.
[42] also demonstrated that EBV exerts a profound effect
on the cellular miRNA profile in EBV-positive NK/T-cell
lymphomas compared to non-infected cases. Other re-
ports have revealed that CCAAT/enhancer binding pro-
tein alpha and nuclear factor I/A regulate mature miR-223
by competing for a regulatory binding site 700 bp up-
stream of the pre-miR-223 sequence [43]. Thus, the
mechanisms that regulate the level of miR-223 remain
to be elucidated.
Conclusions
Collectively, these findings in our study indicate that
PRDM1 is downregulated in EN-NK/T-NT cases and
that PRDM1-positive staining may have prognostic value
for evaluating the prognosis for EN-NK/T-NT patients.
In addition, PRDM1 is likely to be a target of miR-223,
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genetic mechanism of PRDM1 downregulation in EN-
NK/T-NT. miR-223-mediated silencing of PRDM1 pro-
vides new insight into the genetic mechanisms underlying
EN-NK/T-NT and an opportunity to identify new thera-
peutic strategies for EN-NK/T-NT.
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